Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
63%(5 trials)

Phase Distribution

Ph not_applicable
3
27%
Ph phase_3
4
36%
Ph phase_4
1
9%
Ph phase_2
3
27%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
4(36.4%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Other(3)

Detailed Status

Completed8
unknown3

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (27.3%)
Phase 34 (36.4%)
Phase 41 (9.1%)
N/A3 (27.3%)

Trials by Status

completed873%
unknown327%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study

NCT02227992
completednot_applicable

Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

NCT03654560
completedphase_2

Surgicel Reduces Ovarian Endometriomas Recurrence

NCT02947724
completedphase_3

Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection

NCT03489070
unknownphase_2

Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding

NCT03176992
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02227992Phase 3

The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study

Completed
NCT03654560Not Applicable

Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

Completed
NCT02947724Phase 2

Surgicel Reduces Ovarian Endometriomas Recurrence

Completed
NCT03489070Phase 3

Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection

Completed
NCT03176992Phase 2

Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding

Unknown
NCT01731938Phase 3

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

Completed
NCT01754480Phase 3

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Completed
NCT00837954Phase 4

Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis

Completed
NCT02054260Not Applicable

Surgicel® (Fibrillar) in Non-variceal UGI Bleeding

Unknown
NCT00658723Phase 2

The Fibrin Patch Soft Tissue Study

Completed
NCT01756534Not Applicable

Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
11